Among all gynecological malignancies, ovarian cancer is associated with the highest rate of mortality. Most ovarian carcinomas have been suggested to originate from the ovarian surface epithelium or postovulatory inclusion cysts formed after follicular rupture and repair. Over the past decade, a new model has emerged to explain the origin of epithelial tumors of the ovary and the fallopian tube now appears to play a central role; however, there is now compelling evidence that many epithelial pelvic cancers, especially high-grade serous carcinomas of the ovary/peritoneum, begin in the mucosa of the fallopian tube as serous tubal intraepithelial carcinoma.
{"title":"Serous tubal intraepithelial carcinoma: Emerging trend in ovarian neoplasm: A must know for a pathologist","authors":"B. Iqbal","doi":"10.4103/ccij.ccij_46_21","DOIUrl":"https://doi.org/10.4103/ccij.ccij_46_21","url":null,"abstract":"Among all gynecological malignancies, ovarian cancer is associated with the highest rate of mortality. Most ovarian carcinomas have been suggested to originate from the ovarian surface epithelium or postovulatory inclusion cysts formed after follicular rupture and repair. Over the past decade, a new model has emerged to explain the origin of epithelial tumors of the ovary and the fallopian tube now appears to play a central role; however, there is now compelling evidence that many epithelial pelvic cancers, especially high-grade serous carcinomas of the ovary/peritoneum, begin in the mucosa of the fallopian tube as serous tubal intraepithelial carcinoma.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"225 - 226"},"PeriodicalIF":0.1,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42390085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meningioma is a common benign intracranial neoplasm. The incidence of its extracranial extension is rare. Of the meningioma types, meningothelial variety is the most common histological type. Authors report a case of compartmentalized presentation of extradural meningioma in a 35-year-old male who presented to us with a frontal region swelling (exostosis). The patient was evaluated with computed tomography scan of the brain. At surgery, he was found to have compartmentalized presentation of the scalp, calvarium, and dura which we would like to report in this case.
{"title":"A rare case of compartmentalized presentation of extradural meningioma","authors":"S. Gotecha, Prashant Punia, A. Chugh","doi":"10.4103/ccij.ccij_6_21","DOIUrl":"https://doi.org/10.4103/ccij.ccij_6_21","url":null,"abstract":"Meningioma is a common benign intracranial neoplasm. The incidence of its extracranial extension is rare. Of the meningioma types, meningothelial variety is the most common histological type. Authors report a case of compartmentalized presentation of extradural meningioma in a 35-year-old male who presented to us with a frontal region swelling (exostosis). The patient was evaluated with computed tomography scan of the brain. At surgery, he was found to have compartmentalized presentation of the scalp, calvarium, and dura which we would like to report in this case.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"254 - 256"},"PeriodicalIF":0.1,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42712498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Breast cancer (BC) is the most common cancer in Iranian women, with 13400 new cases annually. A few studies have reported that BC patients with a positive familial history had different prognoses and outcomes. The aim of the present study was to evaluate and compare survival between familial BC (FBC) patients and sporadic BC (SBC) patients in Iranian women. Materials and Metshods: In a longitudinal study, 1710 patients with complete medical records from the Cancer Research Center database were extracted and divided into two groups: The FBC group (n = 311) and the SBC group (n = 1399). Then, 5-year overall survival (OS) and 5-year disease-free survival (DFS) for these two groups were evaluated and compared. Results: The FBC group and SBC group represented 18.2% and 81.8% of all cases, with mean ages of 44.2 years and 47.7 years, respectively (P = 0.0024). There were more advanced stage and positive lymph nodes, higher grade of tumor, more positive lymphovascular invasion and P53 status and higher degrees of negative progesterone receptor status in the FBC group than in the SBC group (P = 0.0200, P = 0.0001, P = 0.0001, P = 0.0386, P = 0.0182 and P = 0.0003, respectively). In the FBC group and SBC group, the 5-year DFS was 81% and 86.5% (P = 0.0121), and the 5-year OS was 71.1% and 76.5%, respectively (P = 0.0401). Conclusions: The findings of this study showed better 5-year OS, 5-year DFS, and favorable prognostic factors in the SBT group than in the FBC group. The initial results might be helpful as better treatment modalities and careful follow-up in the FBC group.
{"title":"A comparative survival study between familial and sporadic breast cancer in iranian women","authors":"Amir Shahram Yousefi Kashi","doi":"10.4103/ccij.ccij_25_21","DOIUrl":"https://doi.org/10.4103/ccij.ccij_25_21","url":null,"abstract":"Background: Breast cancer (BC) is the most common cancer in Iranian women, with 13400 new cases annually. A few studies have reported that BC patients with a positive familial history had different prognoses and outcomes. The aim of the present study was to evaluate and compare survival between familial BC (FBC) patients and sporadic BC (SBC) patients in Iranian women. Materials and Metshods: In a longitudinal study, 1710 patients with complete medical records from the Cancer Research Center database were extracted and divided into two groups: The FBC group (n = 311) and the SBC group (n = 1399). Then, 5-year overall survival (OS) and 5-year disease-free survival (DFS) for these two groups were evaluated and compared. Results: The FBC group and SBC group represented 18.2% and 81.8% of all cases, with mean ages of 44.2 years and 47.7 years, respectively (P = 0.0024). There were more advanced stage and positive lymph nodes, higher grade of tumor, more positive lymphovascular invasion and P53 status and higher degrees of negative progesterone receptor status in the FBC group than in the SBC group (P = 0.0200, P = 0.0001, P = 0.0001, P = 0.0386, P = 0.0182 and P = 0.0003, respectively). In the FBC group and SBC group, the 5-year DFS was 81% and 86.5% (P = 0.0121), and the 5-year OS was 71.1% and 76.5%, respectively (P = 0.0401). Conclusions: The findings of this study showed better 5-year OS, 5-year DFS, and favorable prognostic factors in the SBT group than in the FBC group. The initial results might be helpful as better treatment modalities and careful follow-up in the FBC group.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"234 - 240"},"PeriodicalIF":0.1,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46054541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_130_20
R. Kaur, K. Mardi, Lalita Negi, Ankita Dheer
Background: Gastric cancer is the fifth most common cancer in the world. HER2/neu is a proto-oncogene that has a key role in the pathogenesis of several human cancers including gastric cancer. The introduction of trastuzumab has increased overall survival in HER2/neu-positive, locally advanced, and metastatic gastric cancer. Aim: To study the HER2/neu expression in different histopathological types of gastric carcinomas and to correlate its expression with clinicopathological parameters. Materials and Methods: A total of 80 cases of gastric adenocarcinoma that had undergone curative resection from July 2016 to June 2019 were selected for the study. All tumor samples were tested for HER2/neu overexpression and it was correlated with various clinicopathological parameters. Results: In our study, the mean age of patients was 59 years. Majority of the tumors (60%) were located in the pyloric antrum region. Sixty-six percent were intestinal type followed by diffuse (29%) and mixed type (5%). HER2/neu overexpression was seen in 9% of cases. There was no significant correlation between HER2/neu overexpression and age, gender, site, histological type, or grade of the tumor. Conclusion: There was no statistically significant correlation between HER2/neu expression and age, gender, site of tumor, histological type, or differentiation of the tumor. Thus, HER2/neu can be considered as having no prognostic significance in gastric carcinoma.
{"title":"Overexpression of HER2/Neu in gastric adenocarcinoma and its correlation with clinicopathological parameters","authors":"R. Kaur, K. Mardi, Lalita Negi, Ankita Dheer","doi":"10.4103/ccij.ccij_130_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_130_20","url":null,"abstract":"Background: Gastric cancer is the fifth most common cancer in the world. HER2/neu is a proto-oncogene that has a key role in the pathogenesis of several human cancers including gastric cancer. The introduction of trastuzumab has increased overall survival in HER2/neu-positive, locally advanced, and metastatic gastric cancer. Aim: To study the HER2/neu expression in different histopathological types of gastric carcinomas and to correlate its expression with clinicopathological parameters. Materials and Methods: A total of 80 cases of gastric adenocarcinoma that had undergone curative resection from July 2016 to June 2019 were selected for the study. All tumor samples were tested for HER2/neu overexpression and it was correlated with various clinicopathological parameters. Results: In our study, the mean age of patients was 59 years. Majority of the tumors (60%) were located in the pyloric antrum region. Sixty-six percent were intestinal type followed by diffuse (29%) and mixed type (5%). HER2/neu overexpression was seen in 9% of cases. There was no significant correlation between HER2/neu overexpression and age, gender, site, histological type, or grade of the tumor. Conclusion: There was no statistically significant correlation between HER2/neu expression and age, gender, site of tumor, histological type, or differentiation of the tumor. Thus, HER2/neu can be considered as having no prognostic significance in gastric carcinoma.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"209 - 213"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42333342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Oral submucous fibrosis (OSF) is a potentially malignant disorder with 0.4%–10% incidence in India and malignant transformation rate of 3%–19%. Oral squamous cell carcinoma (OSCC) coexistent with OSF exhibits distinct clinicopathological features. Hence, knowledge of the possible mechanism responsible for the epithelial–mesenchymal transition (EMT) of OSF gains importance. The study aims to assess the pattern of p16 and β-catenin expression in normal mucosa (NM), OSF, and OSCC with and without OSF, to correlate with clinicopathological parameters, and to establish association between p16 and β-catenin as markers of EMT. Materials and Methods: Seventy cases, 10 NM, 30 OSF, and 30 OSCC with and without OSF, were subjected to immunohistochemical staining with p16 and β-catenin. Parameters such as percentage positivity and pattern of expression were tabulated and statistically compared using Chi-square test. The combined predictive value of the biomarkers was gauged using discriminant functional analysis. Results: A significant increase in p16% positivity and altered pattern of p16 expression from nuclear to cytoplasmic among the groups (P < 0.001) and a reduced % positivity of β-catenin from NM to OSF and OSCC with and without OSF (P < 0.001). Localization of β-catenin expression shifted from membrane to cytoplasm among groups, which was significantly different in OSCC with and without OSF. The predictive significance of β-catenin and p16 for OSCC with and without OSF was 76.7%. Conclusion: The overexpression of inactivated p16 and synchronous loss of β-catenin expression can be used as an indicator of the early changes during EMT in OSF.
{"title":"Immunohistochemical expression of P16 and β-catenin in oral submucous fibrosis and oral squamous cell carcinoma with or without coexistence of oral submucous fibrosis","authors":"Archana Sudhakaran, K. Hallikeri, Roshni Monteiro","doi":"10.4103/ccij.ccij_75_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_75_20","url":null,"abstract":"Background: Oral submucous fibrosis (OSF) is a potentially malignant disorder with 0.4%–10% incidence in India and malignant transformation rate of 3%–19%. Oral squamous cell carcinoma (OSCC) coexistent with OSF exhibits distinct clinicopathological features. Hence, knowledge of the possible mechanism responsible for the epithelial–mesenchymal transition (EMT) of OSF gains importance. The study aims to assess the pattern of p16 and β-catenin expression in normal mucosa (NM), OSF, and OSCC with and without OSF, to correlate with clinicopathological parameters, and to establish association between p16 and β-catenin as markers of EMT. Materials and Methods: Seventy cases, 10 NM, 30 OSF, and 30 OSCC with and without OSF, were subjected to immunohistochemical staining with p16 and β-catenin. Parameters such as percentage positivity and pattern of expression were tabulated and statistically compared using Chi-square test. The combined predictive value of the biomarkers was gauged using discriminant functional analysis. Results: A significant increase in p16% positivity and altered pattern of p16 expression from nuclear to cytoplasmic among the groups (P < 0.001) and a reduced % positivity of β-catenin from NM to OSF and OSCC with and without OSF (P < 0.001). Localization of β-catenin expression shifted from membrane to cytoplasm among groups, which was significantly different in OSCC with and without OSF. The predictive significance of β-catenin and p16 for OSCC with and without OSF was 76.7%. Conclusion: The overexpression of inactivated p16 and synchronous loss of β-catenin expression can be used as an indicator of the early changes during EMT in OSF.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"189 - 195"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43997984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_178_20
D. Khosla, S. Zaheer, R. Madan, S. Goyal, Narendra Kumar, Rakesh Kapoor
COVID-19 pandemic has challenged the entire health care system to a great extent and led to the development and utilization of alternative approaches. Tele-oncology holds great potential to deliver cancer care. With the use of tele-oncology, physical distancing can be maintained. This will help the cancer patients as well as the oncologist and other supporting staff from getting exposed to the virus. However, there are many challenges for starting tele-oncology especially in resource limited settings. We hereby discuss tele-oncology its applications, methods available, tools, set up and infrastructure, benefits of tele-oncology and various patient, physician and resource-related factors in detail, especially in the setting of low- and middle-income countries.
{"title":"Tele-oncology in cancer care during COVID-19 pandemic-expanding role in the developing world","authors":"D. Khosla, S. Zaheer, R. Madan, S. Goyal, Narendra Kumar, Rakesh Kapoor","doi":"10.4103/ccij.ccij_178_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_178_20","url":null,"abstract":"COVID-19 pandemic has challenged the entire health care system to a great extent and led to the development and utilization of alternative approaches. Tele-oncology holds great potential to deliver cancer care. With the use of tele-oncology, physical distancing can be maintained. This will help the cancer patients as well as the oncologist and other supporting staff from getting exposed to the virus. However, there are many challenges for starting tele-oncology especially in resource limited settings. We hereby discuss tele-oncology its applications, methods available, tools, set up and infrastructure, benefits of tele-oncology and various patient, physician and resource-related factors in detail, especially in the setting of low- and middle-income countries.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"182 - 185"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43187728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_135_20
Rahul Rajagopal, R. Sukumaran, C. Sivanandan, Jayasree Katoor
Background: Neoadjuvant chemoradiotherapy followed by definitive surgery has been well established as the standard treatment for patients with locally advanced rectal cancer. The aims of the study were to assess the various histopathological changes in tumor cells and stroma, to assess the tumor regression grade (TRG) and tumor downstaging after neoadjuvant chemoradiotherapy. Materials and Methods: Ninety cases of carcinoma rectum which received neoadjuvant chemoradiotherapy followed by definitive surgery were included. Pretreatment biopsy slides were assessed for tumor type and differentiation. In postsurgical specimens, pathological assessment of morphological changes, tumor downstaging, and TRG was done. Results: Out of the 90 cases in the study group, the peak incidence was in the age group of 61–70 years (35 cases, 38.9%). The male-to-female ratio was 1.25:1. Moderately differentiated adenocarcinoma was the most common histologic type on biopsy samples, accounting for 86.6% of cases. Complete disappearance of tumor cells or TRG0 was seen in 11 cases (12% of total). TRG1 was seen in 32% of cases, TRG2 in 34% of cases, and TRG3 in 22% of cases. Tumor downstaging was noted in 68% of cases. The most striking histopathological features observed were increased cytoplasmic eosinophilia (58.9%) and marked nuclear pleomorphism (78.9%). The predominant type of stromal response was fibroinflammatory type (53.3% of cases). Conclusion: Pathological evaluation remains the gold standard for assessing the tumor response to neoadjuvant therapy. Accurate assessment of therapy-induced morphologic changes and tumor downstaging is important in further treatment and prognostication of patients.
{"title":"Histopathological assessment of rectal carcinomas after neoadjuvant chemoradiotherapy","authors":"Rahul Rajagopal, R. Sukumaran, C. Sivanandan, Jayasree Katoor","doi":"10.4103/ccij.ccij_135_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_135_20","url":null,"abstract":"Background: Neoadjuvant chemoradiotherapy followed by definitive surgery has been well established as the standard treatment for patients with locally advanced rectal cancer. The aims of the study were to assess the various histopathological changes in tumor cells and stroma, to assess the tumor regression grade (TRG) and tumor downstaging after neoadjuvant chemoradiotherapy. Materials and Methods: Ninety cases of carcinoma rectum which received neoadjuvant chemoradiotherapy followed by definitive surgery were included. Pretreatment biopsy slides were assessed for tumor type and differentiation. In postsurgical specimens, pathological assessment of morphological changes, tumor downstaging, and TRG was done. Results: Out of the 90 cases in the study group, the peak incidence was in the age group of 61–70 years (35 cases, 38.9%). The male-to-female ratio was 1.25:1. Moderately differentiated adenocarcinoma was the most common histologic type on biopsy samples, accounting for 86.6% of cases. Complete disappearance of tumor cells or TRG0 was seen in 11 cases (12% of total). TRG1 was seen in 32% of cases, TRG2 in 34% of cases, and TRG3 in 22% of cases. Tumor downstaging was noted in 68% of cases. The most striking histopathological features observed were increased cytoplasmic eosinophilia (58.9%) and marked nuclear pleomorphism (78.9%). The predominant type of stromal response was fibroinflammatory type (53.3% of cases). Conclusion: Pathological evaluation remains the gold standard for assessing the tumor response to neoadjuvant therapy. Accurate assessment of therapy-induced morphologic changes and tumor downstaging is important in further treatment and prognostication of patients.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"196 - 202"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49666129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_114_20
P. Nagpal, U. Suryanarayana, D. Pruthi, Rakeshkumar Vyas, M. Gohil
Background: Concurrent chemoradiation had been the standard of care for locally advanced oropharyngeal cancers. The addition of newer targeted therapies such as cetuximab has resulted in improved locoregional control rates along with tolerable toxicities. The aim of this study was to evaluate the response with addition of newer generation of systemic targeted agents (gefitinib and erlotinib) in combination with chemoradiotherapy for locally advanced oropharyngeal cancer. Materials and Methods: A total of fifty patients of locally advanced carcinoma oropharynx were randomized by odd–even technique to two arms. Arm A (24 patients) received radiotherapy along with concurrent weekly carboplatin 150 mg and daily gefitinib 250 mg, whereas Arm B (25 patients) received erlotinib 150 mg daily along with same chemoradiation regimen as in arm A. Results: The mean age group in the gefitinib and erlotinib groups was 56.9 and 55.1 years. The most common subsite was base of tongue followed by tonsil. The complete response rate was nearly the same in both the arms at the end of treatment. At the end of 1 and 2 years, the disease-free survival (DFS) was more in the gefitinib group as compared to erlotinib group (41.6% vs. 29.1%) and (33.3% vs. 25%), respectively. Conclusion: There was no significant improvement in DFS and OS with the administration of tyrosine kinase inhibitor (TKI) along with concurrent chemoradiotherapy. This might be attributed to the fact that longer duration of TKI was not administered, variable bioavailability of TKIs, and other immune-dependent mechanism when compared to cetuximab and other monoclonal antibodies.
{"title":"Comparison of concurrent chemoradiation with daily gefitinib versus daily erlotinib in locally advanced oropharyngeal cancers","authors":"P. Nagpal, U. Suryanarayana, D. Pruthi, Rakeshkumar Vyas, M. Gohil","doi":"10.4103/ccij.ccij_114_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_114_20","url":null,"abstract":"Background: Concurrent chemoradiation had been the standard of care for locally advanced oropharyngeal cancers. The addition of newer targeted therapies such as cetuximab has resulted in improved locoregional control rates along with tolerable toxicities. The aim of this study was to evaluate the response with addition of newer generation of systemic targeted agents (gefitinib and erlotinib) in combination with chemoradiotherapy for locally advanced oropharyngeal cancer. Materials and Methods: A total of fifty patients of locally advanced carcinoma oropharynx were randomized by odd–even technique to two arms. Arm A (24 patients) received radiotherapy along with concurrent weekly carboplatin 150 mg and daily gefitinib 250 mg, whereas Arm B (25 patients) received erlotinib 150 mg daily along with same chemoradiation regimen as in arm A. Results: The mean age group in the gefitinib and erlotinib groups was 56.9 and 55.1 years. The most common subsite was base of tongue followed by tonsil. The complete response rate was nearly the same in both the arms at the end of treatment. At the end of 1 and 2 years, the disease-free survival (DFS) was more in the gefitinib group as compared to erlotinib group (41.6% vs. 29.1%) and (33.3% vs. 25%), respectively. Conclusion: There was no significant improvement in DFS and OS with the administration of tyrosine kinase inhibitor (TKI) along with concurrent chemoradiotherapy. This might be attributed to the fact that longer duration of TKI was not administered, variable bioavailability of TKIs, and other immune-dependent mechanism when compared to cetuximab and other monoclonal antibodies.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"203 - 208"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46798483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_172_20
C. Okechukwu
{"title":"Comment on: “The effect of spiritual intervention on the concentration of interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor alpha cytokines in patients with breast cancer: A pretest–posttest experimental study”","authors":"C. Okechukwu","doi":"10.4103/ccij.ccij_172_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_172_20","url":null,"abstract":"","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"223 - 224"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41640877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/ccij.ccij_167_20
K. Mardi, Shantosh A. Sharma
We report an extremely rare case of atypical epithelioid trophoblastic lesion arising from cesarean section scar in a 27-year-old woman with a history of undergoing cesarean delivery 2 years back. The patient presented with amenorrhea and increased frequency of micturition and negative urine pregnancy test. MRI was suggestive of a thin-walled exophytic hemorrhagic cyst arising from the anterior wall of lower uterine segment, communicating with the endometrial cavity. Cyst was excised and histology indicated a lesion consisting of epithelioid trophoblastic cells with an intermediate pattern between a classical placental site nodule and an epithelioid trophoblastic tumor. Immunohistochemistry revealed positivity for CK18, PLAP, and p63. Beta HCG was negative and Ki-67 index was 8%–10%.
{"title":"Atypical postcesarean epithelioid trophoblastic lesion with cyst formation: A rare case report with review of literature","authors":"K. Mardi, Shantosh A. Sharma","doi":"10.4103/ccij.ccij_167_20","DOIUrl":"https://doi.org/10.4103/ccij.ccij_167_20","url":null,"abstract":"We report an extremely rare case of atypical epithelioid trophoblastic lesion arising from cesarean section scar in a 27-year-old woman with a history of undergoing cesarean delivery 2 years back. The patient presented with amenorrhea and increased frequency of micturition and negative urine pregnancy test. MRI was suggestive of a thin-walled exophytic hemorrhagic cyst arising from the anterior wall of lower uterine segment, communicating with the endometrial cavity. Cyst was excised and histology indicated a lesion consisting of epithelioid trophoblastic cells with an intermediate pattern between a classical placental site nodule and an epithelioid trophoblastic tumor. Immunohistochemistry revealed positivity for CK18, PLAP, and p63. Beta HCG was negative and Ki-67 index was 8%–10%.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"10 1","pages":"219 - 222"},"PeriodicalIF":0.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42504610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：